항암화학요법의 구토유발 수준별 예방적 항구토제 프로토콜의 이행정도 = Compliance with the Protocol Considered Emetogenic Potential for Prophylaxis of Chemotherapy Induced Nausea and Vomiting

다국어 초록 (Multilingual Abstract)

Purpose: The purpose of this study was to identify the compliance with the protocol, which was developed considering the emetogenic potential for prophylaxis of chemotherapy. Methods: Data was collected from 144 patients who received chemotherapy from June 15 to August 31, 2010 in C University Hospital in Jeollanamdo, Korea. The level of chemotherapy-induced nausea and vomiting (CINV) and the compliance with the protocol for prophylaxis of CINV were measured. Results: There was statistically significant difference of CINV in morning sickness and anticipatory nausea of general and clinical characteristics. Also, the compliance with the protocol developed according to emetogenic potential of chemotherapy was statistically significant. There was no difference in CINV in regard to the compliance with the protocol. Conclusion: There was a good compliance with the protocol for prophylaxis according to emetogenic potential. But it should be recommended to use antiemetics for prophylaxis aggressively to relieve CINV for the patients who already experienced morning sickness and anticipatory nausea. In addition, the oncology nurses should respond sensitively to the complaints of nausea and vomiting no matter what the emetogenic potentials of chemotherapy regimen are.

목차 (Table of Contents)

• 서론
• 연구 방법
• 연구 결과
• 논의
• 결론 및 제언
• 참고문헌

참고문헌 (Reference)

1 손영수, "저출산 국가위기의 대처 방안" 위기관리 이론과 실천 2 (2): 30-35, 2006

2 Molassiotis A, "Use of antiemtics in the management of chemotherapy-related nausea and vomiting in current UK practice. Support Care Cancer"

3 Rhodes VA, "The index of nausea, vomiting and retching: a new format of the Index of Nausea and Vomiting" 26 : 889-894, 1999

4 Kim YJ, "The index of nausea, vomiting and retching(Korean translation)" 12 : 278-285, 2000

5 Heffinger AI, "The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers" 15 : 526-536, 2004

6 Gralla RJ, "Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology" 17 : 2971-2994, 1999

7 Hesketh PJ, "Proposal for classifying the acute emetogenicity of cancer chemotherapy" 15 : 103-109, 1997

8 Multinational Association of Supportive Care in Cancer, "Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC)" 9 : 811-819, 1998

9 Molassiotis A, "Pretreatment factors predicting the development of postchemotherapy nausea and vomiting in Chinese breast cancer patients" 10 : 139-145, 2001

10 Grélot L, "Potent inhibition of both the acute and delayed emetic responses to cisplatin in piglets treated with GR205171, a novel highly selective tachykinin NK1 receptor antagonist" 124 : 1643-1650, 1998

11 Mertens WC, "Improving the care of patients with regard to chemotherapy induced nasuea and emesis: The effect of feedback to clinicians on adherence to antiemetic prescribing guidelines" 21 : 1373-1378, 2003

12 Jordan K, "Guidelines for antiemetic treatment of chemotherapy induced nausea and vomiting: past. present, future recommendations" 12 : 1143-1150, 2007

13 Oh CY, "Evaluation of antiemetic therapy after the administration of high-dose antineoplastic agents: Focused Ondansetron" 16 : 495-500, 1999

14 National Comprehensive Cancer Network, "Effective interventions for CINV: NCCN Antiemesis Clinical Practice Guidelines in Oncology" 19 (19): 17-18, 2004

15 European Society for Medical Oncology, "ESMO recommendations for prophylaxis of chemotherapy-induced nauseaand vomiting (NV)" 12 (12): 1059-1060, 2001

16 Rhodes VA, "Criteria for assessment of nausea, vomiting, and retching" 24 (24): 13-19, 1997

17 Shih V, "Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide" 43 : 444-452, 2009

18 Asan Medical Center Cancer Center, "Clinical practice guideline for Chemotherapy" Koonja publishers 2009

19 Herrstedt J, "Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis" 19 (19): 110-112, 2008

20 Warr DG, "Chemotherapy-and cancer-related nausea and vomiting" 15 (15): 4-9, 2008

21 정규원, "Cancer Statistics in Korea: Incidence, Mortality and Survival in 2006-2007" 대한의학회 25 (25): 1113-1121, 2010

22 Wickham R, "Best practice management of CINV in oncology patient: II. Antiemetic guideline and retionale for use" 8 (8): 10-15, 2010

23 Kris MG, "American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006" 24 : 2932-2947, 2006

24 Kris MG, "American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006" 24 : 2932-2947, 2006